Radha Rajasingham

Summary

Publications

  1. doi request reprint Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort
    Radha Rajasingham
    University of Minnesota, Minneapolis, Minnesota Infectious Disease Institute, Makerere University, Kampala, Uganda Minnesota Department of Health, St Paul, Minnesota Centers for Disease Control and Prevention, Fort Collins, Colorado Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
    Am J Trop Med Hyg 92:274-9. 2015
  2. pmc Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care
    Radha Rajasingham
    Infectious Disease Institute, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 59:e85-91. 2012
  3. pmc A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine
    Radha Rajasingham
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Patient Care STDS 26:36-52. 2012
  4. pmc Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis
    David R Boulware
    From the University of Minnesota, Minneapolis D R B, D B M, M A R, K H H, D A W, R R, J R, M W L, K N, T L B, P R B the Infectious Disease Institute D B M, A M, H W N, D A W, R R, J R, M W L, A K, Y C M and School of Medicine, College of Health Sciences D B M, Makerere University, Kampala, and Mbarara University of Science and Technology, Mbarara C M, K T both in Uganda the University of Cape Town, Cape Town, South Africa C S, F T, G M Johns Hopkins School of Medicine, Baltimore Y C M the Mucosal and Vaccine Research Program Colorado MAVRC, University of Colorado Denver, Aurora
    N Engl J Med 370:2487-98. 2014
  5. pmc Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study
    Renee Donahue Carlson
    Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 3 222 MTRF, 2001 6th St SE, Minneapolis, MN, 55455, USA
    Metab Brain Dis 29:269-79. 2014
  6. pmc Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100
    Richard Kwizera
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    PLoS ONE 9:e103156. 2014
  7. pmc Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis
    Radha Rajasingham
    Infectious Disease Institute, Makerere University, Kampala, Uganda
    PLoS Med 9:e1001316. 2012

Collaborators

Detail Information

Publications8

  1. doi request reprint Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort
    Radha Rajasingham
    University of Minnesota, Minneapolis, Minnesota Infectious Disease Institute, Makerere University, Kampala, Uganda Minnesota Department of Health, St Paul, Minnesota Centers for Disease Control and Prevention, Fort Collins, Colorado Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
    Am J Trop Med Hyg 92:274-9. 2015
    ..Exploration of new TB diagnostics and diagnostic algorithms for evaluation of meningitis in resource-limited settings remains needed, and implementation of cryptococcal diagnostics is critical. ..
  2. pmc Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care
    Radha Rajasingham
    Infectious Disease Institute, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 59:e85-91. 2012
    ..We provide recommendations for implementation, pre-emptive treatment, and identify the gaps in our current knowledge...
  3. pmc A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine
    Radha Rajasingham
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Patient Care STDS 26:36-52. 2012
    ..The results presented support efforts to develop and implement novel interventions to reduce crystal meth use in HIV-infected MSM...
  4. pmc Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis
    David R Boulware
    From the University of Minnesota, Minneapolis D R B, D B M, M A R, K H H, D A W, R R, J R, M W L, K N, T L B, P R B the Infectious Disease Institute D B M, A M, H W N, D A W, R R, J R, M W L, A K, Y C M and School of Medicine, College of Health Sciences D B M, Makerere University, Kampala, and Mbarara University of Science and Technology, Mbarara C M, K T both in Uganda the University of Cape Town, Cape Town, South Africa C S, F T, G M Johns Hopkins School of Medicine, Baltimore Y C M the Mucosal and Vaccine Research Program Colorado MAVRC, University of Colorado Denver, Aurora
    N Engl J Med 370:2487-98. 2014
    ..Antiretroviral therapy (ART) is essential for survival; however, the question of when ART should be initiated after diagnosis of cryptococcal meningitis remains unanswered...
  5. pmc Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study
    Renee Donahue Carlson
    Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 3 222 MTRF, 2001 6th St SE, Minneapolis, MN, 55455, USA
    Metab Brain Dis 29:269-79. 2014
    ..Few characteristics related to severity of cryptococcosis, including Cryptococcus burden, were associated with neurocognitive outcome. ..
  6. pmc Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100
    Richard Kwizera
    Infectious Diseases Institute, Makerere University, Kampala, Uganda
    PLoS ONE 9:e103156. 2014
    ..These require invasive lumbar punctures. The utility of cryptococcal antigen detection in saliva is unknown. We evaluated the diagnostic performance of the point-of-care cryptococcal antigen lateral flow assay (CrAg LFA) in saliva...
  7. pmc Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis
    Radha Rajasingham
    Infectious Disease Institute, Makerere University, Kampala, Uganda
    PLoS Med 9:e1001316. 2012
    ..A cost-effectiveness analysis was performed to guide stakeholders with respect to optimal CM treatment within resource limitations...